MAPK7 and glioblastoma: In addition to identifying ERK5 as a potential novel drug target to augment TMZ effectiveness in glioblastoma treatment regimes, to our knowledge, we also provide the first target validation data for ERK5 in glioblastoma by directly assessing ERK5 mRNA and protein expression within glioblastoma patient cohorts.